S&P Futures
5,875.75 -20.50 (-0.35%) Dow Futures
43,044.00 -133.00 (-0.31%) Nasdaq Futures
20,439.00 -80.50 (-0.39%) Russell 2000 Futures
2,245.00 -10.50 (-0.47%) Crude Oil
71.23 +0.67 (+0.95%) Gold
2,747.70 +8.80 (+0.32%)
Photocure ASA (PHO.OL)
- PR Newswire
Photocure Partner Asieris Unveils Cevira (APL-1702) Phase III Subgroup Analysis by Age Groups at the 2024 CSCO Annual Meeting
Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated that international multicenter Phase III clinical study data for its non-surgical treatment candidate Cevira® (APL-1702) for cervical High-Grade Squamous Intraepithelial Lesion (HSIL) has been published by the 27th Chinese Society of Clinical Oncology (CSCO) Annual Meeting as a poster, focusing on the analysis of different age subgroups regarding the six-month patho
- PR Newswire
Photocure establishes Named Patient Program to provide access to Hexvix in South Africa
Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that it entered into an agreement with Equity Pharmaceuticals PTY Limited, part of the Clinigen group, in September, to initiate a Named Patient Program (NPP) enabling bladder cancer patients in South Africa to receive blue light cystoscopy (BLC®) with Hexvix®.
